DR. CHRISTINA MÜLLER

Chief Operating Officer — Pharmaceutical

Personal Info

Phone
+49 151 2298765

E-mail
c.mueller@email.com

LinkedIn
linkedin.com/in/christinamueller

Skills

- cGMP Operations
- Drug Launch
- M&A Integration
- Quality Systems
- Digital Manufacturing
- Board Reporting
- Regulatory Affairs
- P&L Oversight

Languages

German
Intermediate

Accomplished pharmaceutical executive with 20+ years of progressive leadership in global drug manufacturing, supply chain, and commercial operations. Track record of leading multi-billion-dollar product launches, managing cGMP facilities across 3 continents, and building high-performance teams of 2,000+. PhD in Biochemistry (ETH Zürich) combined with executive education from Harvard Business School.

Experience

Chief Operating Officer

European Pharma AG, Basel | April 2020 – Present

- Full operational accountability for a $4.2B pharmaceutical business spanning 12 manufacturing sites and 6,500 employees globally.
- Orchestrated the scale-up and commercial launch of two blockbuster biologics, generating $1.8B in first-year combined revenue.
- Drove digital transformation of manufacturing operations, deploying AI-based quality prediction models that reduced batch failures by 45%.
- Led the integration of a $2.1B acquisition, consolidating manufacturing footprint from 15 to 12 sites while increasing output capacity by 20%.

SVP Manufacturing & Supply

Global BioPharma Inc., Frankfurt | January 2015 – March 2020

- Directed all manufacturing and supply operations for a $2.8B biologics portfolio across 8 sites in Europe and Asia.
- Led the successful FDA and EMA pre-approval inspections for 3 new manufacturing facilities with zero critical findings.
- Managed an annual CAPEX budget of $450M for facility expansions and technology upgrades.
- Built and led a cross-functional team of 120 for the company's first cell and gene therapy commercial manufacturing capability.

VP Quality & Compliance

Swiss Pharma Solutions, Zürich | March 2010 – December 2014

- Oversaw quality systems for 5 manufacturing sites, ensuring continuous compliance with FDA, EMA, and PMDA regulations.
- Resolved a critical FDA Warning Letter within 8 months, restoring full regulatory standing.
- Implemented a risk-based quality management system that reduced deviations by 55% and investigations cycle time by 40%.

Education

Executive Education, General Management Program
Harvard Business School — 2018

PhD Biochemistry
ETH Zürich — 2003

M.Sc. Molecular Biology
University of Heidelberg — 1999